Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis

Leone, José Pablo; Leone, Julieta; Zwenger, Ariel Osvaldo; Iturbe, Julian; Leone, Bernardo Amadeo; Vallejo, Carlos

doi:10.1016/j.ejca.2016.12.015

Cited by 33 publications

(30 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent large study, it has been noted that presence of metastases at other visceral locations such as liver or lung had an important negative impact on OS. 7 Similar to the literature, the outcome of our study indicates that PS > 1 was correlated with a worse OS (P = 0.04, 95% CI = 0.196-1.003). Some series analyzing surgical strategies for multiple BM revealed no correlation between BM's number and OS.…”

Section: Survival and Prog Nos Ti C Fac To R Ssupporting

confidence: 89%

“…In our cohort, patients with a number of metastatic sites < 2 had a significantly better OS ( P = 0.008). In a recent large study, it has been noted that presence of metastases at other visceral locations such as liver or lung had an important negative impact on OS . Similar to the literature, the outcome of our study indicates that PS > 1 was correlated with a worse OS ( P = 0.04, 95% CI = 0.196‐1.003).…”

Section: Survival and Prognostic Factorssupporting

confidence: 87%

See 1 more Smart Citation

Therapeutic results and prognostic factors of brain metastases from breast cancer: Single center experience

et al. 2019

View full text Add to dashboard Cite

Section: Survival and Prog Nos Ti C Fac To R Ssupporting

confidence: 89%

Section: Survival and Prognostic Factorssupporting

confidence: 87%

Therapeutic results and prognostic factors of brain metastases from breast cancer: Single center experience

et al. 2019

View full text Add to dashboard Cite

“…Liver metastasis from breast cancer is a heterogeneous disease and its outcome varies significantly among tumor subtypes (12). In our study, the median survival among these patients with HR-positive HER2-positive and HR-negative HER2-positive subtype were 31.0 months and 22.0 months, respectively, experiencing longer median survival than other subtypes.…”

Section: Discussionmentioning

confidence: 52%

“…Notably, liver metastases are present in only 3% to 8% of patients with breast cancer at the time of the initial diagnosis and are typically associated with metastases at other sites (10,11). As a result, the changes caused by distant relapse and treatment exposure could be potential confounding factors in the prognostic assessment (12). In addition, the prognosis of patients with liver metastases from breast cancer is usually extremely poor, with 5-year survival rates of only 3.8% to 12% (6,(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

A Population-Based Study on Liver Metastases in Women with Newly Diagnosed Breast Cancer

Xie

2019

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Population-based estimates for prognosis among patients with liver metastases in newly diagnosed breast cancer are not generally available.Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, we identified 298,370 patients with breast cancer and 4,285 patients diagnosed with initial liver metastases between 2010 and 2014. Data were stratified according to subtype, age, and race. Multivariate logistic and Cox regression were used to identify predictors for the presence of initial liver metastases and prognostic factors, respectively. Kaplan-Meier procedure was used for survival analysis.Results: A total of 4,285 patients with initial liver metastases (1.4% of the entire cohort, 29.6% of the subset with metastatic disease) were identified. Patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (4.4% of entire cohort, 52.5% of patients with metastatic disease to any distant site) and HR-positive HER2-positive (2.8% of entire cohort, 40.4% of patients with metastatic disease to any distant site) subtypes had highest incidence proportions. The median survival of patients with liver metastases in the entire cohort was 15.0 months. Patients with HR-positive HER2-positive subtype showed the longest median survival (31.0 months); however, patients with triplenegative subtype showed the shortest median survival (8.0 months).Conclusions: Our findings provide population-based estimates of epidemiologic characteristics and prognosis in breast cancer patients diagnosed with initial liver metastases.Impact: This study lends support to the diagnosis of the liver among patients at high risk of liver metastases, including those with HER2-positive and other systemic metastases.

show abstract

“…There is growing evidence indicating that patterns of metastases vary between different hormone receptor (HR) and human epithelial growth factor receptor 2 (HER2) statuses of breast tumors 11, 12, 13, 14, 15, 16, 17, 18. Patients with HR‐positive breast cancer are at increased risk for the development of bone metastases, whereas bone metastases are less frequent in cases of triple‐negative tumors 15, 16, 17, 18, 19, 20, 21.…”

Section: Introductionmentioning

confidence: 99%

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

Gong

Zhang

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

IntroductionPopulation‐based data on the incidence and prognosis of bone metastases at diagnosis of breast cancer are currently limited. Hence, we conducted this study to analyze the incidence proportions and prognostic factors of patients with breast cancer and bone metastases at the time of cancer diagnosis.Materials and methodsPatients with primary invasive breast cancer and bone metastases at initial diagnosis between 2010 and 2014 were identified using the Surveillance, Epidemiology, and End Results (SEER) dataset and Fudan University Shanghai Cancer Center (FUSCC) cohort. Multivariable logistic regression was performed to identify predictors of the presence of bone metastases at diagnosis. Univariate and multivariate analyses were performed to determine the effects of each variable on survival.ResultsOf 229, 195 patients from SEER database included in the analysis, 8295 patients had bone metastases at initial diagnosis, reflecting 3.6% of the entire study population, and 65.1% of the subset with metastatic disease to any distant site. Patients with hormone receptor (HR)‐positive human epidermal growth factor receptor 2 (HER2)‐negative represented the highest incidence proportions among patients with metastatic disease (73.9%). Among entire cohort, multivariable logistic regression identified eight factors as predictors of the presence of bone metastases at diagnosis. Median OS for the patients with bone metastases in SEER and FUSCC cohorts was 30.0 and 68.2 months, respectively. Patients with HR‐positive HER2‐positive subtype had the longest median OS, and patients with triple‐negative subtype showed the shortest median OS. Multivariable Cox model in SEER cohort confirmed age, histology, grade, tumor subtype, extraosseous metastatic sites, history of primary surgery, insurance status, marital status, and income as independent prognostic factors for both OS and BCSS.ConclusionsThe findings of this study provide population‐based estimates of the incidence and prognosis for patients with bone metastases at initial diagnosis of breast cancer.

show abstract

Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis

Cited by 33 publications

References 27 publications

Therapeutic results and prognostic factors of brain metastases from breast cancer: Single center experience

Therapeutic results and prognostic factors of brain metastases from breast cancer: Single center experience

A Population-Based Study on Liver Metastases in Women with Newly Diagnosed Breast Cancer

Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

Contact Info

Product

Resources

About